Saturday 17 October 2026 Export TTOO’s income statement to Excel — free account

T2 Biosystems, Inc.

T2 Biosystems, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $7.2 million, down 67.8% from fiscal 2022. Operating cash flow growth for three consecutive years.

0.00 0.00 NaN

Follow TTOO

Alert me

Market cap: $6.5M
P/E: 0.0×
Fwd P/E: −0.6×
Dividend yield: —
F-score: 2/9
Altman Z: −28.92
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 55.62%

Capital & Financial Ratios $m

Market Cap 6.48

Revenue 7.68

Net Income (42.95)

Free Cash Flow (36.59)

Net Debt (2.08)

Current Ratio 0.40

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.59)

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 83.85%

Next Y EPS Growth 61.61%

Next Y revenue growth 47.37%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

EV/Sales against its own 10 years 67.52%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2021	2022	2023	Q'24
Cash	32	10	16	2
Receivables	5	2	1	2
Inventory	4	4	5	4
Other	—	—	—	—
	44	19	25	10

	2021	2022	2023	Q'24
Payables	3	1	2	4
ST’ Debt	—	—	—	—
Other	8	0	2	0
	12	10	56	24

Compound Annual Growth %

	10y	5y	3y
Sales	39.06%	(7.29%)	(26.52%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	2	2	2	—	—
’23	2	2	1	2	7
’22	7	6	4	5	22
’21	7	7	7	7	28
’20	3	3	5	8	18
’19	2	2	2	3	8
’18	2	4	2	2	11

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(12)	(9)	(6)	—	—
’23	(13)	(12)	(13)	(9)	(48)
’22	(14)	(10)	(16)	(10)	(51)
’21	(9)	(11)	(10)	(10)	(39)
’20	(15)	(13)	(6)	(9)	(43)
’19	(13)	(9)	(14)	(10)	(45)
’18	(12)	(9)	(10)	(10)	(40)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(12)	(9)	(6)	—	—
’23	(13)	(12)	(13)	(9)	(48)
’22	(14)	(10)	(16)	(10)	(51)
’21	(9)	(11)	(10)	(10)	(39)
’20	(15)	(14)	(7)	(9)	(44)
’19	(13)	(9)	(14)	(10)	(46)
’18	(12)	(9)	(10)	(9)	(41)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(2.66)	(0.66)	(0.57)	—	—
’23	(132.00)	(8.00)	(3.45)	123.88	(19.19)
’22	(500.00)	(500.00)	(295.00)	69.09	(1.23k)
’21	(350.00)	(400.00)	(400.00)	(350.00)	(1.55k)
’20	(1.10k)	(450.00)	(400.00)	(350.00)	(1.95k)
’19	(1.70k)	(1.75k)	(1.55k)	(1.50k)	(6.50k)
’18	(1.80k)	(1.60k)	(1.25k)	(1.75k)	(6.30k)

Fiscal quarters ending in the months shown.

Group	Line	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e
Price, $
Price, $	Low	—	—	489.00	250.00	294.00	52.00	23.50	45.00	5.12	3.36	Analyst estimates 2024–2026 Powerpack
	High	—	—	1,130.00	699.00	998.00	538.00	231.00	379.00	292.50	210.99
People
People	Employees	—	—	178	161	153	151	148	182	158	113
	Revenue/emp, $m	—	—	0.02	0.03	0.07	0.06	0.12	0.15	0.14	0.06
Income, $m
Income, $m	Revenue	—	—	4	5	11	8	18	28	22	7
	Gross margin, %	—	—	(68.43)	(157.78)	(46.70)	(101.12)	(17.37)	26.21	5.81	(113.58)
	EBT	—	—	(55)	(62)	(51)	(59)	(47)	(49)	(62)	(50)
	EBT margin, %	—	—	(1,343.24)	(1,337.93)	(487.17)	(707.93)	(258.12)	(175.50)	(277.98)	(696.19)
	Net income	—	—	(55)	(62)	(51)	(59)	(47)	(49)	(62)	(50)
	Depreciation	—	—	2	3	2	4	3	3	1	1
Per share, $
Per share, $	Revenue	—	—	784.62	729.06	1,296.30	915.93	746.09	882.33	437.35	2.76
	Earnings	—	—	(10,500.00)	(9,449.30)	(6,300.00)	(6,500.00)	(1,950.00)	(1,550.00)	(1,228.00)	(19.19)
	Cash flow	—	—	(8,931.15)	(7,455.94)	(4,955.31)	(4,984.73)	(1,778.40)	(1,222.45)	(992.73)	(18.44)
	Capex	—	—	(1,055.19)	(386.87)	(73.21)	(83.63)	(32.92)	(14.47)	(6.65)	(0.07)
	Free cash flow	—	—	(9,986.35)	(7,842.81)	(5,028.52)	(5,068.35)	(1,811.32)	(1,236.92)	(999.37)	(18.52)
	Book value	—	—	7,565.00	209.38	1,405.80	(3,736.81)	359.09	(405.75)	(777.55)	(10.74)
	Shares, m	—	—	0	0	0	0	0	0	0	3
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	0.67	0.61	0.23	0.13	0.17	0.06	0.37	1.96
	P/B	—	—	0.07	2.12	0.21	0.00	0.35	0.00	0.00	0.00
	EV/Sales	—	—	(7.47)	(7.98)	(4.56)	(0.97)	0.33	0.61	2.13	6.75
	EV/FCF	—	—	0.59	0.74	1.18	0.18	(0.14)	(0.44)	(0.93)	(1.00)
Cash, $m
Cash, $m	Operating cash flow	—	—	(46)	(48)	(40)	(45)	(43)	(39)	(51)	(48)
	Capex	—	—	(5)	(2)	(1)	(1)	(1)	0	0	0
	Free cash flow	—	—	(52)	(50)	(41)	(46)	(44)	(39)	(51)	(48)
Balance, $m
Balance, $m	Working capital	—	—	66	(7)	4	(42)	44	33	9	(31)
	Total debt	—	—	40	2	0	2	45	48	50	—
	Net debt	—	—	(33)	(40)	(50)	(9)	3	16	39	(16)
	Shareholders’ equity	—	—	39	1	11	(34)	9	(13)	(40)	(28)
Returns, %
Returns, %	ROA	—	—	(62.14)	(86.45)	(85.85)	(127.17)	(87.01)	(70.54)	(131.41)	(144.89)
	ROIC	—	—	(517.39)	0.00	0.00	0.00	(219.57)	(1,015.05)	0.00	0.00
	ROE	—	—	(127.04)	(306.94)	(803.85)	521.76	370.25	2,357.72	237.20	147.96

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2023 · latest quarter Sep 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PMD Psychemedics Corporation	$15.7M	— (loss-making)	— (loss-making)	−11.46% (below 0%: shrinking)	n/m	+57.45% (above 0%: growing)	31.37%	3.80%	Compare
ADVB Advanced Biomed Inc.	$8.1M	0.8×	—	—	n/m	−101.33% (below 0%: shrinking)	—	0.00%	Compare
NDRA ENDRA Life Sciences Inc.	$7.7M	— (loss-making)	— (loss-making)	−98.80% (below 0%: shrinking)	n/m	+15.04% (above 0%: growing)	0.00%	0.00%	Compare
XWEL XWELL, Inc.	$7.5M	— (loss-making)	— (loss-making)	−7.08% (below 0%: shrinking)	n/m	−43.02% (below 0%: shrinking)	41.26%	(29.45%)	Compare
TTOO T2 Biosystems, Inc.	$6.5M	— (loss-making)	— (loss-making)	+34.85% (above 0%: growing)	n/m	+53.36% (above 0%: growing)	(106.60%)	(511.89%)
BIAF bioAffinity Technologies, Inc.	$5.1M	— (loss-making)	— (loss-making)	+18.99% (above 0%: growing)	n/m	−23.69% (below 0%: shrinking)	27.98%	(220.77%)	Compare
DMTKQ DermTech, Inc.	$3.3M	— (loss-making)	— (loss-making)	+10.58% (above 0%: growing)	n/m	+24.87% (above 0%: growing)	18.54%	(533.37%)	Compare
NOTVQ Inotiv, Inc.	$2.8M	— (loss-making)	— (loss-making)	−5.37% (below 0%: shrinking)	n/m	+82.66% (above 0%: growing)	20.95%	(16.41%)	Compare
ISPC iSpecimen Inc.	$2.6M	— (loss-making)	— (loss-making)	−78.70% (below 0%: shrinking)	n/m	−257.73% (below 0%: shrinking)	45.23%	(897.30%)	Compare
Median of peers	$6.3M	—	—	−7.08%	—	−4.32%	27.98%	(22.93%)

All 52 Diagnostics & Research stocks →

T2 Biosystems, Inc. (TTOO) key facts

Concern: T2 Biosystems, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $7.2 million, down 67.8% from fiscal 2022.
T2 Biosystems, Inc. (TTOO) is a Diagnostics & Research company in the Healthcare sector.
Return on equity was 148.0% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −28.92 (distress zone) for fiscal 2023.

Source: company filings (standardised) and stockrow calculations.